Elevation Oncology, INC

Elevation Oncology, Inc. has finalized its merger with Concentra Biosciences, LLC's subsidiary, resulting in the company becoming a private entity and its shares being delisted from Nasdaq.

Elevation Oncology, Inc. has terminated its License Agreement with CSPC Megalith Biopharmaceutical Co., Ltd. for the Claudin 18.2 antibody-drug conjugate EO-3021, following the discontinuation of its development.

Elevation Oncology, an innovative oncology company, has entered into a definitive merger agreement to be acquired by Concentra Biosciences for $0.36 per share in cash plus a non-tradeable contingent value right tied to net cash and future disposition of its HER3 ADC product candidate, EO-1022.

Elevation Oncology reported its Q1 2025 financial results, highlighting preclinical data for EO-1022 and a cash runway into the second half of 2026.

Elevation Oncology voluntarily prepaid its $32.3 million term loan, fully discharging all related obligations and releasing security interests on its assets.

Elevation Oncology announces its intention to prepay its $30 million term loan, plus fees and interest, totaling approximately $32.2 million, to K2 HealthVentures LLC.

Elevation Oncology discontinues EO-3021 development, focuses on EO-1022, and initiates a strategic review to maximize shareholder value in its Q1 2025 report.

Elevation Oncology's Q3 2024 report highlights progress in the EO-3021 clinical trial and financial updates, including a net loss of $12.9 million.

Elevation Oncology's Q2 2024 report highlights progress in its EO-3021 clinical trial and financial updates, including a net loss of $10.5 million.

Elevation Oncology's first quarter 2024 results show a net loss of $10.7 million, but the company's cash position has improved to $104.1 million.

Elevation Oncology's 10-K filing summarizes the company's financial performance in 2024 and provides updates on its clinical development programs, including EO-3021 and EO-1022.

Elevation Oncology is advancing its lead drug candidate, EO-3021, through clinical trials while also developing a HER3-targeting ADC program.

Elevation Oncology, Inc. Director Alan B. Sandler reported the disposition of stock options as the company completed its merger with Concentra Biosciences, LLC, involving a tender offer of $0.36 cash per share plus a contingent value right.

Elevation Oncology Director Darcy Mootz disposed of all stock options as part of the company's merger with Concentra Biosciences, receiving cash and contingent value rights.

Elevation Oncology director Steve Elms disposed of all stock options on July 23, 2025, as part of the company's merger with Concentra Biosciences, receiving cash and contingent value rights for eligible options.

Elevation Oncology Director Timothy P. Clackson disposed of all common stock and converted stock options as part of the company's acquisition by Concentra Biosciences for $0.36 per share plus a contingent value right.

Elevation Oncology, Inc. Director Julie M. Cherrington disposed of all her stock options as part of the company's acquisition by Concentra Biosciences, LLC.

Elevation Oncology director R. Michael Carruthers disposed of stock options as part of the company's acquisition by Concentra Biosciences, with most options cancelled for no consideration due to exercise prices exceeding the cash offer.

Elevation Oncology's upcoming annual meeting on June 5, 2025, will include proposals for director elections, auditor ratification, and a potential reverse stock split.

Elevation Oncology is asking stockholders to approve a reverse stock split to boost its share price and maintain its Nasdaq listing.

Elevation Oncology announces its 2024 Annual Meeting of Stockholders to be held virtually on June 13, 2024, with key voting items including the election of directors and ratification of the independent accounting firm.

Elevation Oncology will hold its 2024 Annual Meeting of Stockholders virtually on June 13, 2024, to vote on the election of directors and ratification of the company's independent accounting firm.

BML Investment Partners, L.P. has filed an amended Schedule 13D, indicating zero beneficial ownership of Elevation Oncology, Inc. common stock after the completion of a tender offer for all outstanding shares.

BML Investment Partners, holding a 9.9% stake in Elevation Oncology, has formally urged the company's Board of Directors to pursue an orderly winddown, liquidation, and return of capital to shareholders, citing unfavorable market conditions and poor performance of recent biopharma reverse mergers.

Tang Capital Management and affiliates report a 4.997% beneficial ownership stake in Elevation Oncology, Inc., primarily through exercisable warrants.

Frazier Life Sciences and its affiliates have reported a complete divestment of their beneficial ownership in Elevation Oncology, Inc., reducing their stake to 0.0%.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a passive beneficial ownership of 0.6% of Elevation Oncology, Inc.'s common stock as of June 30, 2025.

A group of investment entities led by Biotechnology Value Fund and Mark N. Lampert has disclosed a combined beneficial ownership of 7.0% in Elevation Oncology, Inc., primarily through exercisable warrants.

Tang Capital Management, LLC and its affiliated entities, including Kevin Tang, have disclosed a continued passive beneficial ownership of 9.99% in Elevation Oncology, Inc., comprising common stock and currently exercisable warrants.

Farallon Capital and its affiliated entities have filed an amended Schedule 13G, indicating they no longer beneficially own any shares of Elevation Oncology, Inc.'s common stock as of March 31, 2025.